Applied Biosystems/MDS Analytical Technologies Launches New Mass Spectrometry Tools to Advance Public Health and Safety
01 Juni 2009 - 1:30PM
Business Wire
Applied Biosystems, a division of Life Technologies Corporation
(NASDAQ:LIFE), and its mass spectrometry joint-venture partner, MDS
Analytical Technologies, a business unit of MDS Inc. (TSX:MDS)
(NYSE:MDZ), today announced the commercial availability of new mass
spectrometry tools to help laboratories in a variety of industries
advance their efforts to improve public health and safety. The
Cliquid� 3.0 Software application and mTRAQ� triplex reagents are
designed to enhance food and water contaminant testing, forensic
drug screening and protein biomarker research.
Cliquid� 3.0 Software is an automated software application for
contaminant testing and forensic analysis. It enables scientists to
identify unknown compounds, expanding the scope of Cliquid software
to identify the greatest number of compounds and driving the
life-science industry�s most comprehensive solution for food and
water contaminant testing as well as forensic drug screening for
emerging variations of illicit drugs. mTRAQ� triplex reagents are a
set of chemical reagents that label proteins in complex samples for
targeted quantitation. They make biomarker verification more
accurate, doubling the throughput of analysis, which is expected to
accelerate the use of increasing numbers of biomarkers in clinical
settings.
These tools, which are optimized for Applied Biosystems/MDS
Analytical Technologies mass spectrometers, including the AB SCIEX
5500 Systems and AB SCIEX TOF/TOF 5800 System, enable scientists to
increase their ability to use mass spectrometry systems to identify
and quantify compounds or contaminants. For example, food testing
laboratories can detect unknown contaminants that may be present in
the food supply, while forensic laboratories may be able to
identify new designer street drugs in forensic investigations. In
the proteomics field, researchers can more rapidly verify and
validate biomarkers to support their potential use in clinical
settings, including the emergence of personalized medicine.
Laura Lauman, President of Life Technologies� Mass
Spectrometry Systems Division
�Scientists in a variety of industries are continuing to employ
the power of mass spectrometry to advance their efforts in
improving public health and safety. Applied Biosystems/MDS
Analytical Technologies continues to support these scientists by
providing them with innovative technologies that deliver complete
workflow solutions, including industry-leading platforms, software
and applications.�
Andy Boorn, President of MDS Analytical Technologies
�Applied Biosystems/MDS Analytical Technologies continues to
drive new standards for mass spectrometry-based software
applications to maximize the innovation of our platforms. We are
evolving our technologies to provide the highest-performing tools,
responding to customer requirements to expand the capabilities of
laboratories.�
Additional Resources
Food Testing Solutions
Biomarker Solutions
About Applied Biosystems Products
Applied Biosystems is a global leader in providing innovative
instrument systems to accelerate academic and clinical research,
drug discovery and development, pathogen detection and forensic DNA
analysis. Applied Biosystems, along with Invitrogen � a leading
provider of platform independent, essential life science
technologies for disease and drug research, bioproduction and
diagnostics � is part of Life Technologies. Applied Biosystems and
Invitrogen products are used in nearly every major laboratory in
the world. For more information, please visit:
www.appliedbiosystems.com and www.invitrogen.com.
About Life Technologies
Life Technologies Corporation (NASDAQ:LIFE) is a global
biotechnology tools company dedicated to improving the human
condition. Our systems, consumables and services enable researchers
to accelerate scientific exploration, driving to discoveries and
developments that make life even better. Life Technologies
customers do their work across the biological spectrum, working to
advance personalized medicine, regenerative science, molecular
diagnostics, agricultural and environmental research, and 21st
century forensics. Life Technologies had sales of more than $3
billion in 2008, employs approximately 9,500 people, has a presence
in more than 100 countries, and possesses a rapidly growing
intellectual property estate of approximately 3,600 patents and
exclusive licenses. Life Technologies was created by the
combination of Invitrogen Corporation and Applied Biosystems Inc.
For more information on how we are making a difference please visit
our website: www.lifetechnologies.com.
About MDS Analytical Technologies
MDS Analytical Technologies, a business unit of MDS Inc.
(TSX:MDS) (NYSE:MDZ), is focused on the research, design,
manufacture and marketing of state-of-the-art tools for
mass-spectrometry, drug discovery and bioresearch. MDS Analytical
Technologies� products are designed to help accelerate the complex
process of discovering and developing new drug compounds, and are
sold to research scientists around the world. The mass-spectrometer
product lines are also sold globally through joint ventures with
two of the world�s leading analytical instrumentation and
life-sciences companies, Life Technologies Corporation and
PerkinElmer, Inc. Find out more at www.mdssciex.com or
www.moleculardevices.com.
Life Technologies Safe Harbor Statement
This press release includes forward-looking statements about
Life Technologies� anticipated results that involve risks and
uncertainties. Some of the information contained in this press
release, including, but not limited to, statements as to industry
trends and Life Technologies� plans, objectives, expectations and
strategy for its business, contains forward-looking statements that
are subject to risks and uncertainties that could cause actual
results or events to differ materially from those expressed or
implied by such forward-looking statements. Any statements that are
not statements of historical fact are forward-looking statements.
When used, the words �believe,� �plan,� �intend,� �anticipate,�
�target,� �estimate,� �expect� and the like, and/or future tense or
conditional constructions (�will,� �may,� �could,� �should,� etc.),
or similar expressions, identify certain of these forward-looking
statements. Important factors which could cause actual results to
differ materially from those in the forward-looking statements are
detailed in filings made by�Life Technologies with the Securities
and Exchange Commission.�Life Technologies undertakes no obligation
to update or revise any such forward-looking statements to reflect
subsequent events or circumstances.
Copyright 2009. Life Technologies Corporation. All rights
reserved. Cliquid and mTRAQ are registered trademarks of Applied
Biosystems/MDS Analytical Technologies, a joint venture between
Applied Biosystems LLC and MDS Inc.
Mds (NYSE:MDZ)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
Mds (NYSE:MDZ)
Historical Stock Chart
Von Okt 2023 bis Okt 2024